Antifungal susceptibility of Aspergillus species isolated from invasive oral infection in neutropenic patients with hematologic malignancies

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 87, Issue 2, 1999, Pages 174-179

  Myoken, Yoshinari ^a,c   Sugata, Tatsumi ^a   Myoken, Yoshiko ^a   Kyo, Tai Ichi ^a   Fujihara, Megumu ^a   Mikami, Yuzuru ^b  

^a Department of Dentistry and Oral Surgery ^*

^b 1 8 1 Inohana Chuo ku 260 8670   (Japan)

^c ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICONAZOLE;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; LEUKEMIA; LYMPHOMA; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MOUTH DISEASE; NEUTROPENIA;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG COMBINATIONS; DRUG EVALUATION; FEMALE; FLUCONAZOLE; FLUCYTOSINE; HUMANS; IMMUNOCOMPROMISED HOST; ITRACONAZOLE; LEUKEMIA; LYMPHOMA; MALE; MICONAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOUTH DISEASES; NEUTROPENIA;

EID: 0033071582     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-2104(99)70269-6     Document Type: Article

References (23)

1. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992;14(Suppl):120-5.
2. Fraser RS. Pulmonary aspergillosis: pathologic and pathogenetic features. Pathology Annual 1993;28:231-77.
3. Young RC, Bennett JE, Vogel CL, et al. Aspergillosis: the spectrum of the disease in 98 patients. Medicine 1970;49:147-73.
4. Dreizen S, Keating MJ, Beran M. Orofacial fungal infections: nine pathogens that may invade during chemotherapy. Postgrad Med 1992;91:349-64.
5. Colman MF. Invasive aspergillosis of the head and neck. Laryngoscope 1985;95:898-9.
6. Viollier A-F, Peterson DE, Jongh CAD, et al. Aspergillus sinusitis in cancer patients. Cancer 1986;58:3660-71.
7. Choi SS, Milmoe GJ, Dinndorf PA, et al. Invasive Aspergillus sinusitis in pediatric bone marrow transplant patients: evaluation and management. Arch Otolaryngol Head Neck Surg 1995;121:1188-92.
8. Lusk SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345-51.
9. Yamada H, Kohno S, Maesaki S, et al. Rapid and highly reproducible method for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 1993;31:1009-12.
10. Denning DW, Hanson LH, Perlman AM, et al. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992;15:21-34.
11. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791-800.
12. Sugata T, Myoken Y, Kyo T, Fujihara M. Invasive oral aspergillosis in immunocompromised patients with leukemia. J Oral Maxillofac Surg 1994;52:382-6.
13. Myoken Y, Sugata T, Kyo T, Fujihara M. Pathologic features of invasive oral aspergillosis in patients with hematologic malignancies. J Oral Maxillofac Surg 1996;54:263-70.
14. Mossad SB, Longworth DL, Goormastic M, et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996;18:265-71.
15. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts: approved standard M27-1. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1997.
16. Boon-Long J, Mekha N, Poonwan N, et al. In vitro antifungal activity of the new triazole DO 870 against Penicillium marneffei compared with that of amphotericin B, fluconazole, itraconazole, miconazole, and flucytosine. Mycoses 1996;39:453-6.
17. Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995;39:314-9.
18. Mikami Y, Sakamoto T, Yazawa K, et al. Comparison of in vitro antifungal activity of itraconazole and hydroxy-itraconazole by colorimetric MTT assay. Mycoses 1994;37:27-33.
19. Karp JE. Burch PA, Merz WG. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 1988;85:203-6.
20. Hughes CE, Harris C, Moody JA, Peterson LR, Gerding DN. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Antimicrob Agents Chemother 1984;25:560-2.
21. Kerkering TM, Espinel-Ingroff A. In vitro synergistic activity of itraconazole and 5-fluorocytosine against Aspergillus fumigatus and Aspergillus flavus. In: Fromtling RA, editor. Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona, Spain: JR Prous Science; 1987. p. 61.
22. Odds FC. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother 1987;22:763-70.
23. Saag Ms, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988;32:1-8.